---
title: "Enveric Biosciences Expands At-The-Market Equity Offering"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289247934.md"
description: "Enveric Biosciences filed a prospectus supplement to offer an additional $2.425 million in common stock under its at-the-market agreement with H.C. Wainwright & Co., following prior sales of $4.48 million. This equity issuance aims to support financing needs but may dilute existing shareholders. TipRanks' AI analyst rates ENVB as Neutral, citing weak financials, negative earnings, and technical downtrends, despite recent governance updates."
datetime: "2026-06-09T22:51:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289247934.md)
  - [en](https://longbridge.com/en/news/289247934.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289247934.md)
---

# Enveric Biosciences Expands At-The-Market Equity Offering

Enveric Biosciences ( (ENVB) ) just unveiled an update.

On June 9, 2026, Enveric Biosciences, Inc. filed a prospectus supplement to offer an additional $2.425 million of common stock under its existing at-the-market offering agreement with H.C. Wainwright & Co., LLC. Prior to this filing, the company had already sold approximately $4.48 million of shares through the same agreement, underscoring its continued use of equity issuance to raise capital and support its financing needs.

The filing also noted that a legal opinion on the validity of the newly issuable shares was submitted in connection with the prospectus supplement. This step formalizes the company’s capacity to sell more stock under the at-the-market program, potentially affecting existing shareholders through further dilution while enhancing Enveric’s financial flexibility for ongoing or future initiatives.

**Spark’s Take on ENVB Stock**

According to Spark, TipRanks’ AI Analyst, ENVB is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, large ongoing losses, and continued cash burn with a limited equity cushion), with technicals also pointing to a downtrend (below major moving averages and negative MACD). Valuation is difficult to support due to negative earnings and no dividend, while recent corporate actions (reverse split authorization and governance updates) are a modest offset but not a fundamental improvement.

To see Spark’s full report on ENVB stock,  
click here.

**More about Enveric Biosciences**

Enveric Biosciences, Inc. operates in the biotechnology and pharmaceutical sector, focusing on the development of novel therapies, with its equity securities traded as common stock. The company accesses capital markets through structured equity programs, including at-the-market offerings managed by investment banks, to fund its operations and development pipeline.

**Average Trading Volume:** 3,802,564

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $6.44M

Find detailed analytics on ENVB stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ENVB.US](https://longbridge.com/en/quote/ENVB.US.md)

## Related News & Research

- [Enveric welcomes final FDA guidance on psychedelic drug trials](https://longbridge.com/en/news/294062160.md)
- [IC Group hires Adelaide Capital to expand investor outreach, plans North America roadshows and digital campaigns](https://longbridge.com/en/news/294878586.md)
- [Is paying artists enough to convince them to embrace AI?](https://longbridge.com/en/news/294607299.md)
- [Leopold Aschenbrenner just learned Wall Street's oldest lesson: Chart of the day](https://longbridge.com/en/news/294606560.md)
- [CrowdStrike Stock And Cybersecurity Peers For The Rising AI Breach Threat](https://longbridge.com/en/news/294574764.md)